Pfizer Inc.

1
Pfizer Inc.

• (PFE)
• Healthcare Sector

2
Sector Holdings

• 42,743 or 31,035 (2nd-3rd largest sector)
• AMGN
• Global biotech
• BRL
• Global pharmaceuticals
• MDT
• Medical device technology
• UNH
• Diversified health

3
Company Profile

• Global pharmaceutical company
• Human Health
• Lipitor, Norvasc, Zoloft, Celebrex, Xalatan,
  Viagra
• Consumer Healthcare
• Listerine, Nicorette, Benadryl, Sudafed, Rogaine,
  Zantac, Rolaids, Neosporin, Visine, Lubriderm,
  Purell
• Animal Health
• Parasiticides-fleas, heartworm
• Acquired Embrex (2007 ), Idun (2005),and Vicuron
  (2005)

4
12-Month Price Chart
5
3-Month Price Chart
Torcetrapib, Lipitor
6
50-Day Moving Average
7
Growth Prospects

• Sales reps banned from AIDS Foundation
• Cut 10,000 jobs in Ireland, Canada, US
• Closed research centers Germany, Japan, France
• FDA approved Sutent kidney cancer
• Lost patent suit to Chinese Viagra
• Barr launched generic Zoloft
• Maraviroc-block HIV (safety issues)

8
EPS Trends
9
Key Ratios

• Market Cap 188.46B
• P/E 9.92
• Debt/Equity .116
• EBITDA 20.46B
• EPS 2.66
• Qtrly Rev. Growth (yoy) -7.30
• Beta .69
• Price/Tangible Book 8.19
• D.C.F. 22.84

10
Conclusion

• Purchased prior to 2003
• 306 shares down 31 (-3,628.44)
• Saving 1B by 2008 for flat revenue
• Generic competition
• Failure to introduce new drugs
• Novartis, Merck, Bayer (comp. adv.?)
• Just collected dividend
• Buylist.com fund managers selling